G M Verduijn1, E M de Wee1, Z Rijnen1, P Togni1, J A U Hardillo2, I Ten Hove3, M Franckena1, G C van Rhoon1, M M Paulides1. 1. a Department of Radiation Oncology , Erasmus MC Cancer Institute , Rotterdam , Netherlands. 2. b Department of Otorhinolaryngology-Head and neck surgery , Erasmus MC Cancer Institute , Rotterdam , Netherlands. 3. c Department of Oral and Maxillofacial Surgery-Head and Neck Surgery , Erasmus MC Cancer Institute , Rotterdam , Netherlands.
Abstract
PURPOSE: Radiotherapy (RT) treatment of locally-advanced and recurrent head and neck carcinoma (HNC) results in disappointing outcomes. Combination of RT with cisplatin or cetuximab improves survival but the increased toxicity and patient's comorbidity warrant the need for a less-toxic radiosensitizer. Stimulated by several randomized studies demonstrating the radio-sensitizing effect of hyperthermia, we developed the HYPERcollar. Here, we report early experience and toxicity in patients with advanced HNC. METHODS AND MATERIALS: 119 hyperthermia treatments given to 27 patients were analyzed. Hyperthermia was applied once a week by the HYPERcollar aimed at achieving 39-43 °C in the target area, up to patients' tolerance. Pre-treatment planning was used to optimize treatment settings. When possible, invasive thermometry catheters were placed. RESULTS: Mean power applied during the 119 hyperthermia treatments ranged from 120 to 1007 W (median 543 W). 15 (13%) hyperthermia treatments were not fully completed due to: pain allocated to hyperthermia (6/15), dyspnea from sticky saliva associated with irradiation (2/15) and unknown reasons (7/15). No severe complications or enhanced thermal or mucosal toxicities were observed. Excluding post-operative treatment, response rates after 3 months were 46% (complete) and 7% (partial). CONCLUSION: Hyperthermia with the HYPERcollar proved to be safe and feasible with good compliance and promising outcome.
PURPOSE: Radiotherapy (RT) treatment of locally-advanced and recurrent head and neck carcinoma (HNC) results in disappointing outcomes. Combination of RT with cisplatin or cetuximab improves survival but the increased toxicity and patient's comorbidity warrant the need for a less-toxic radiosensitizer. Stimulated by several randomized studies demonstrating the radio-sensitizing effect of hyperthermia, we developed the HYPERcollar. Here, we report early experience and toxicity in patients with advanced HNC. METHODS AND MATERIALS: 119 hyperthermia treatments given to 27 patients were analyzed. Hyperthermia was applied once a week by the HYPERcollar aimed at achieving 39-43 °C in the target area, up to patients' tolerance. Pre-treatment planning was used to optimize treatment settings. When possible, invasive thermometry catheters were placed. RESULTS: Mean power applied during the 119 hyperthermia treatments ranged from 120 to 1007 W (median 543 W). 15 (13%) hyperthermia treatments were not fully completed due to: pain allocated to hyperthermia (6/15), dyspnea from sticky saliva associated with irradiation (2/15) and unknown reasons (7/15). No severe complications or enhanced thermal or mucosal toxicities were observed. Excluding post-operative treatment, response rates after 3 months were 46% (complete) and 7% (partial). CONCLUSION:Hyperthermia with the HYPERcollar proved to be safe and feasible with good compliance and promising outcome.
Entities:
Keywords:
Hyperthermia; head and neck carcinoma; irradiation
Authors: H Petra Kok; Erik N K Cressman; Wim Ceelen; Christopher L Brace; Robert Ivkov; Holger Grüll; Gail Ter Haar; Peter Wust; Johannes Crezee Journal: Int J Hyperthermia Date: 2020 Impact factor: 3.914
Authors: Gerben Schooneveldt; Hana Dobšíček Trefná; Mikael Persson; Theo M de Reijke; Klas Blomgren; H Petra Kok; Hans Crezee Journal: Cancers (Basel) Date: 2019-08-15 Impact factor: 6.639
Authors: Tomas Drizdal; Gerard C van Rhoon; Rene F Verhaart; Ondrej Fiser; Margarethus M Paulides Journal: Cancers (Basel) Date: 2021-12-05 Impact factor: 6.639